In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Intercept Pharmaceuticals, Inc.. Trade Record

NASDAQ:ICPT Intercept Pharmaceuticals, Inc. stock gains 10.73% Exit Apr 19, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ICPT Apr 3, 2018, priceSeries
About Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.20
Entry Date
Apr 3, 2018
Entry Price
62.83
Sell Date
Apr 19, 2018
Sell Price
69.57
Net Gain
10.73%
Hold Time
12 Trading Days